secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2022-07-18T23:59:59+00:00
Accession:  0001213900-22-039976
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics appoints Hannah Fry as Controller and CEO as principal financial officer after CFO departure
--------------------------------------------------------------------------------

- Blaine Davis departed as CFO on July 15, 2022.
- Hannah Fry appointed Controller effective July 16, 2022, with $255,000 base salary and 25,000 RSU award.
- CEO Jesse Shefferman appointed as principal financial officer of the company.
- Fry's severance includes six months base salary and pro-rata equity vesting on certain awards.
- Fry previously served as Senior Director, Assistant Controller at Protara.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/ea162974-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-039976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer